CD274 and testicular cancer: The first in-human study of CX-072 (pacmilimab), a probody ICI targeting PD-L1, combined with the anti-CTLA-4 antibody ipilimumab, examined 27 patients reporting a tolerable profile at a recommended phase 2 dose of 10 mg/kg as well as preliminary efficacy with an overall response rate of 19%, including one testicular cancer patient who had a partial response which was durable for >12 months [78].